CN117460748A - 抗nkg2a抗体和组合物 - Google Patents

抗nkg2a抗体和组合物 Download PDF

Info

Publication number
CN117460748A
CN117460748A CN202280039227.XA CN202280039227A CN117460748A CN 117460748 A CN117460748 A CN 117460748A CN 202280039227 A CN202280039227 A CN 202280039227A CN 117460748 A CN117460748 A CN 117460748A
Authority
CN
China
Prior art keywords
amino acid
antibody
seq
acid sequence
nkg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280039227.XA
Other languages
English (en)
Chinese (zh)
Inventor
R·W·汉森
F·K·乌伦布罗克
N·迪特里希
A·沃索
M·M·格兰达尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of CN117460748A publication Critical patent/CN117460748A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202280039227.XA 2021-06-01 2022-05-31 抗nkg2a抗体和组合物 Pending CN117460748A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163195470P 2021-06-01 2021-06-01
US63/195,470 2021-06-01
PCT/EP2022/064703 WO2022253805A1 (en) 2021-06-01 2022-05-31 Anti-nkg2a antibodies and compositions

Publications (1)

Publication Number Publication Date
CN117460748A true CN117460748A (zh) 2024-01-26

Family

ID=82117230

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280039227.XA Pending CN117460748A (zh) 2021-06-01 2022-05-31 抗nkg2a抗体和组合物

Country Status (17)

Country Link
US (2) US12012450B2 (https=)
EP (1) EP4347651A1 (https=)
JP (1) JP2024520577A (https=)
KR (1) KR20240016991A (https=)
CN (1) CN117460748A (https=)
AR (1) AR126001A1 (https=)
AU (1) AU2022286617A1 (https=)
BR (1) BR112023024772A2 (https=)
CA (1) CA3222040A1 (https=)
CL (1) CL2023003562A1 (https=)
CO (1) CO2023015982A2 (https=)
IL (1) IL308695A (https=)
MX (1) MX2023014320A (https=)
PE (1) PE20240372A1 (https=)
PH (1) PH12023553123A1 (https=)
TW (1) TW202313683A (https=)
WO (1) WO2022253805A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025168052A1 (en) * 2024-02-08 2025-08-14 Hanx Biopharmaceuticals, (Wuhan) Ltd. Nkg2a/cd94-targeting antibodies and uses thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024140820A1 (zh) * 2022-12-28 2024-07-04 浙江博锐生物制药有限公司 抗nkg2a抗体及其用途
WO2024260280A1 (en) * 2023-06-21 2024-12-26 Elpiscience (Suzhou) Biopharma, Ltd. Antibodies or antigen-binding fragments binding to nkg2a and uses thereof
CN121108342B (zh) * 2025-09-08 2026-03-03 北京明璨生物科技有限公司 包含抗体和nk细胞的组合物在治疗癌症中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
KR20100110864A (ko) * 2008-01-24 2010-10-13 노보 노르디스크 에이/에스 인간화된 항-인간 ｎｋｇ2ａ 모노클로날 항체
SG10202007781TA (en) 2014-09-16 2020-09-29 Innate Pharma Treatment Regimens Using Anti-NKG2A Antibodies
US10329348B2 (en) * 2014-10-23 2019-06-25 Innate Pharma Treatment of cancers using anti-NKG2A agents
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
PH12018502112B1 (en) 2016-04-12 2024-03-27 Servier Lab Anti-tim-3 antibodies and compositions
US12534526B2 (en) 2018-11-07 2026-01-27 Shanghai Hyamab Biotech Co., Ltd. NKG2A antibody, preparation method therefor and application thereof
CN113316590B (zh) * 2018-11-16 2025-02-28 百时美施贵宝公司 抗nkg2a抗体及其用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025168052A1 (en) * 2024-02-08 2025-08-14 Hanx Biopharmaceuticals, (Wuhan) Ltd. Nkg2a/cd94-targeting antibodies and uses thereof

Also Published As

Publication number Publication date
US20220389100A1 (en) 2022-12-08
TW202313683A (zh) 2023-04-01
US12012450B2 (en) 2024-06-18
AU2022286617A1 (en) 2023-12-21
CO2023015982A2 (es) 2024-01-15
PE20240372A1 (es) 2024-03-05
EP4347651A1 (en) 2024-04-10
AR126001A1 (es) 2023-08-30
CA3222040A1 (en) 2022-12-08
WO2022253805A1 (en) 2022-12-08
JP2024520577A (ja) 2024-05-24
KR20240016991A (ko) 2024-02-06
BR112023024772A2 (pt) 2024-02-15
MX2023014320A (es) 2023-12-13
PH12023553123A1 (en) 2024-03-04
IL308695A (en) 2024-01-01
CL2023003562A1 (es) 2024-07-12
US20240294638A1 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
CN115023439B (zh) 抗cd73抗体
US12012450B2 (en) Anti-NKG2A antibodies and compositions
US12252539B2 (en) Anti-FLT3 antibodies and compositions
US11807688B2 (en) Anti-AXL antibodies and compositions
US20210214454A1 (en) Anti-cd40 antibodies and compositions
HK40106092A (zh) 抗nkg2a抗体和组合物
RU2837590C1 (ru) Антитела против axl и композиции
RU2837590C9 (ru) Антитела против axl и композиции
RU2836004C1 (ru) Антитела и композиции против flt3
HK40081002A (en) Anti-axl antibodies and compositions
HK40084729A (en) Anti-flt3 antibodies and compositions
EA052808B1 (ru) Антитела и композиции против flt3

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40106092

Country of ref document: HK